Aveni Foundation Press Releases - EIN Presswire - Press Release Distribution Service

Published on October 26, 2026 - 06:35 GMT

The Sarcoma Oncology Center Announces Promising Clinical Data for DeltaRex-G Gene Therapy at ESMO 2026, Madrid, Spain

Data Update demonstrates significant clinical benefit and survival improvements in advanced, chemoresistant sarcomas, pancreas, breast and ovarian cancer LOS ANGELES, CA, UNITED STATES, October 26, 2026 /⁨EINPresswire.com⁩/ -- The Sarcoma Oncology Center/ …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on September 23, 2026 - 10:00 GMT

FDA CBER Authorizes Direct Injection of DNG64-CAR-V Gene Therapy into CSF for 2nd Patient with Leptomeningeal Disease

An innovative way of administering DNG64-CAR-V for treatment of brain tumors, leukemia, lymphoma and cancers that have spread to the brain and spinal cord, LOS ANGELES, CA, UNITED STATES, September 23, 2026 /⁨EINPresswire.com⁩/ -- The Cancer Center of …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on August 27, 2026 - 10:00 GMT

FDA Authorizes Injection of Tumor Targeted Gene Therapy Directly into Cerebrospinal Fluid for Leptomeningeal Disease

DNG64-CAR-V (DeltaRex-G), A Novel Off-The-Shelf Intraventricular Gene Therapy for Brain Tumors, Leukemia, Lymphoma and Cancers That Have Spread to the Brain LOS ANGELES, CA, UNITED STATES, August 27, 2026 /⁨EINPresswire.com⁩/ -- Aveni Foundation is proud …

Distribution channels: ...

Published on September 24, 2024 - 23:01 GMT

DELTAREX-G FOR CAR-T CELL THERAPY INDUCED CYTOKINE RELEASE SYNDROME

AUTHORS PUBLISH ON THE USE OF DELTAREX-G IN CAR-T CELL THERAPY INDUCED CYTOKINE RELEASE SYNDROME (Front. Mol. Med. 4: doi: 10.3389/fmmed.2024.1461151) LOS ANGELES, CA, UNITED STATES, September 24, 2024 /⁨EINPresswire.com⁩/ -- The Aveni Foundation and …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on April 15, 2024 - 13:00 GMT

DELTAREX-G TUMOR AGNOSTIC THERAPY SHOWS CLINICAL BENEFIT IN CHEMORESISTANT STAGE 4 SARCOMA, PANCREATIC AND BREAST CANCER

AUTHORS REPORT ENHANCED CCNG1 EXPRESSION IN 137 SARCOMA, PANCREAS AND BREAST CANCER TUMORS (https://doi.org/10.1158/1538-7445.AM2024-5183) LOS ANGELES, CALIFORNIA, USA, April 15, 2024 /⁨EINPresswire.com⁩/ -- The Aveni Foundation and the Sarcoma Oncology …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Published on December 11, 2023 - 14:00 GMT

AVENI FOUNDATION PUBLISHES "FROM MENDEL TO GENE THERAPY" MAPPING THE HISTORY OF GENETIC MEDICINE

DELTAREX-G IS THE FIRST TUMOR TARGETED GENE VECTOR TO GAIN ACCELERATED APPROVAL IN 2007. SANTA MONICA, CALIFORNIA, UNITED STATES OF AMERICA, December 11, 2023 /⁨EINPresswire.com⁩/ -- The Aveni Foundation and the Cancer Center of Southern California …

Distribution channels: Banking, Finance & Investment Industry, Education ...

Published on October 24, 2023 - 21:11 GMT

AI ANALYSIS SHOWS ENHANCED CCNG1 EXPRESSION IN SARCOMA: A NOVEL BIOMARKER FOR DELTAREX-G CCNG1 INHIBITOR THERAPY

PRESENTED BY DR. SANT P. CHAWLA AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY LOS ANGELES, CALIFORNIA, UNITED STATES OF AMERICA, October 24, 2023 /⁨EINPresswire.com⁩/ -- The Aveni Foundation and the Sarcoma Oncology Research Center, Santa Monica CA, are …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on August 3, 2023 - 13:00 GMT

DELTAREX-G EXPANDS USFDA AUTHORIZED ACCESS TO BREAST CANCER, PANCREAS CANCER, OSTEOSARCOMA & SOFT TISSUE SARCOMA

USFDA authorizes DeltaRex-G to be used as platform therapy upon which FDA approved cancer drugs may be added for better cancer control (NCT#04091295). LOS ANGELES, CALIFORNIA, UNITED STATES OF AMERICA, August 3, 2023 /⁨EINPresswire.com⁩/ -- The Aveni …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on July 17, 2023 - 07:02 GMT

UK PHILANTHROPISTS SIMONE AND PAUL COMMINS DONATED GBP 1oo,ooo FOR DELTAREX-G CANCER RESEARCH

Working towards a cure for advanced sarcoma LOS ANGELES, CA, USA, July 17, 2023 /⁨EINPresswire.com⁩/ -- Who: Simone and Paul Commins, a UK businessman who has curated a successful trading career, donated GBP 100,000 to Aveni Foundation for DeltaRex-G …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on July 7, 2023 - 07:27 GMT

GUSTAVO SANTAOLALLA, TWO-TIME OSCAR WINNING FILM COMPOSER, PERFORMS A UNIQUE SOLO PRESENTATION FOR AVENI FOUNDATION

SAVE THE DATE: SEPTEMBER 30, 2023 FOR THIS EXCITING EVENT IN BEVERLY HILLS, CALIFORNIA LOS ANGELES, CALIFORNIA, UNITED STATES, July 7, 2023 /⁨EINPresswire.com⁩/ -- Who: Two-Time Oscar Winning multi-instrumentalist, songwriter, producer and composer, …

Distribution channels: Healthcare & Pharmaceuticals Industry, Movie Industry ...

Published on May 18, 2022 - 13:00 GMT

DELTAREX-G AS FRONT-LINE TREATMENT FOR EARLY-STAGE BREAST CANCER SHOWS HEARTENING RESULTS

First woman to receive DeltaRex-G as front-line treatment has no evidence of cancer recurrence. SANTA MONICA, CA, UNITED STATES, May 18, 2022 /⁨EINPresswire.com⁩/ -- Contact: Dr. Erlinda Maria Gordon, 818-726-3278, egordon@sarcomaoncology.com Who: A 75 …

Distribution channels: Healthcare & Pharmaceuticals Industry, Insurance Industry ...

Published on September 22, 2021 - 07:11 GMT

Little Boy Fighting Cancer Desperately needs Experimental Treatment as a Last Hope

Youngest Patient to Receive DeltaRex-G, an Innovative Gene Targeted Cancer Therapy SANTA MONICA, CA, UNITED STATES, September 22, 2021 /⁨EINPresswire.com⁩/ -- Who: 11 year old Kian is fighting a rare cancer. This brave boy moved to Southern California …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on June 28, 2021 - 06:43 GMT

DELTAREX-G GAINS FDA AUTHORIZATION AS ADJUVANT THERAPY FOR EARLY-STAGE TRIPLE NEGATIVE METAPLASTIC BREAST CANCER

PREVENTING RECURRENCE OF TRIPLE NEGATIVE BREAST CANCER WITH TUMOR-TARGETED GENE THERAPY LOS ANGELES, CALIFORNIA, UNITED STATES, June 27, 2021 /⁨EINPresswire.com⁩/ -- The Aveni Foundation (www.avenifoundation.org), and the Cancer Center of Southern …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on January 4, 2021 - 14:00 GMT

DELTAREX-G GAINS FDA AUTHORIZATION AS FIRST-LINE THERAPY FOR EARLY-STAGE TRIPLE RECEPTOR POSITIVE BREAST CANCER

PREVENTING RECURRENCE WITH TUMOR-TARGETED GENE THERAPY: A LITMUS TEST LOS ANGELES, CA, UNITED STATES, January 4, 2021 /⁨EINPresswire.com⁩/ -- The Aveni Foundation (www.avenifoundation.org), and the Cancer Center of Southern California (www. …

Distribution channels: Amusement, Gaming & Casino, Banking, Finance & Investment Industry ...

Published on December 21, 2020 - 18:42 GMT

DELTAREX-G GAINS EMERGENCY USE AUTHORIZATION FOR SEVERE COVID-19

A TARGETED GENE THERAPY FOR COVID-19 INDUCED ARDS LOS ANGELES, CA, USA, December 21, 2020 /⁨EINPresswire.com⁩/ -- The Aveni Foundation (www.avenifoundation.org), in collaboration with Larkin Community Hospital, South Miami FL, Drs. Ellie Soheili and …

Distribution channels: Aviation & Aerospace Industry, Banking, Finance & Investment Industry ...

Published on November 11, 2020 - 14:00 GMT

TUMOR MARKERS FOR DELTAREX-G GENE THERAPY, THE SAFER CHECKPOINT INHIBITOR FOR SARCOMA

A BEACON IN OUR CAMPAIGN AGAINST SARCOMA LOS ANGELES, CA, UNITED STATES, November 11, 2020 /⁨EINPresswire.com⁩/ -- The Aveni Foundation and the Sarcoma Oncology Center / Cancer Center of Southern California, Santa Monica, CA, USA, are proud to announce …

Distribution channels: Aviation & Aerospace Industry, Banking, Finance & Investment Industry ...

Published on October 27, 2020 - 13:00 GMT

CORONA STUDY USING DELTAREX-G FOR COVID-19

Available now: “Right to Try” DeltaRex-G for COVID-19 EMERGENCY USE LOS ANGELES, CA, UNITED STATES, October 27, 2020 /⁨EINPresswire.com⁩/ -- The Aveni Foundation is proud to announce its new mission to treat COVID-19 induced pneumonia/Acute Respiratory …

Distribution channels: Banking, Finance & Investment Industry, Conferences & Trade Fairs ...

Published on October 26, 2020 - 17:00 GMT

DELTAREX-G IMPEDES TUMOR GROWTH IN STAGE 4 CHEMOTHERAPY RESISTANT BONE CANCER

Made possible by the Right to Try law of 2018 and the revival of a “tumor-targeted gene therapy” LOS ANGELES, CA, UNITED STATES, October 26, 2020 /⁨EINPresswire.com⁩/ -- The Aveni Foundation and the Cancer Center of Southern California are proud to …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on April 27, 2020 - 05:26 GMT

DeltaRex-G Tumor-targeted Gene Therapy for Chemotherapy- Induced Leukemia

Harvard and Mayo Clinic Investigators report a new clinical indication for DeltaRex-G genetic medicine. LOS ANGELES, CALIFORNIA, USA, April 26, 2020 /⁨EINPresswire.com⁩/ -- The Aveni Foundation is proud to announce the publication of a novel treatment for …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on August 19, 2019 - 07:07 GMT

USFDA GRANTS EXPANDED ACCESS FOR DELTAREX-G, A PRECISION TUMOR TARGETED GENETIC MEDICINE FOR METASTATIC CANCER(S)

“Expanded Access for DeltaRex-G and Right to Try law will give individuals with different types of cancer a chance to benefit from this innovative treatment." SANTA MONICA, CA, UNITED STATES, August 19, 2019 /⁨EINPresswire.com⁩/ -- The Aveni …

Distribution channels: Healthcare & Pharmaceuticals Industry ...